|
GB9518953D0
(en)
|
1995-09-15 |
1995-11-15 |
Pfizer Ltd |
Pharmaceutical formulations
|
|
EP1272467A4
(en)
|
2000-04-06 |
2003-05-07 |
Merck Frosst Canada Inc |
Cathepsin cysteine protease inhibitors
|
|
PE20060777A1
(es)
|
2004-12-24 |
2006-10-06 |
Boehringer Ingelheim Int |
Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
|
|
SG174050A1
(en)
|
2006-04-13 |
2011-09-29 |
Actelion Pharmaceuticals Ltd |
Endothelin receptor antagonists for early stage idiopathic pulmonary fibrosis
|
|
TWI433677B
(zh)
|
2007-06-04 |
2014-04-11 |
Avila Therapeutics Inc |
雜環化合物及其用途
|
|
US20090264431A1
(en)
|
2007-08-20 |
2009-10-22 |
Palovich Michael R |
Novel cathepsin c inhibitors and their use
|
|
WO2009129365A1
(en)
|
2008-04-18 |
2009-10-22 |
Glaxo Group Limited |
Cathepsin c inhibitors
|
|
WO2009129370A1
(en)
|
2008-04-18 |
2009-10-22 |
Glaxo Group Limited |
Cathepsin c inhibitors
|
|
WO2009129371A1
(en)
|
2008-04-18 |
2009-10-22 |
Glaxo Group Limited |
Cathepsin c inhibitors
|
|
US20120309820A1
(en)
|
2011-06-04 |
2012-12-06 |
Jb Therapeutics Inc. |
Methods of treating fibrotic diseases using tetrahydrocannabinol-11-oic acids
|
|
EP2565186A1
(en)
|
2011-09-02 |
2013-03-06 |
Hybrigenics S.A. |
Selective and reversible inhibitors of ubiquitin specific protease 7
|
|
WO2014175370A1
(ja)
*
|
2013-04-25 |
2014-10-30 |
塩野義製薬株式会社 |
ピロリジン誘導体およびそれらを含有する医薬組成物
|
|
RS58361B1
(sr)
|
2013-07-31 |
2019-03-29 |
Merck Patent Gmbh |
Piridini, pirimidini i pirazini, kao inhibitori btk i njihova upotreba
|
|
US9963444B2
(en)
|
2014-05-19 |
2018-05-08 |
Northeastern University |
N-acylethanolamine hydrolyzing acid amidase (NAAA) inhibitors and their use thereof
|
|
US20170095457A1
(en)
|
2014-05-27 |
2017-04-06 |
David Lonergan |
Compositions and methods of delivery of deubiquitinase inhibitors
|
|
WO2016019237A2
(en)
|
2014-07-31 |
2016-02-04 |
Pharmacyclics Llc |
Inhibitors of bruton's tyrosine kinase
|
|
GB201416754D0
(en)
|
2014-09-23 |
2014-11-05 |
Mission Therapeutics Ltd |
Novel compounds
|
|
CA2976741C
(en)
|
2015-03-30 |
2023-01-17 |
Mission Therapeutics Limited |
1-cyano-pyrrolidine compounds as usp30 inhibitors
|
|
WO2017009650A1
(en)
|
2015-07-14 |
2017-01-19 |
Mission Therapeutics Limited |
Cyanopyrrolidines as dub inhibitors for the treatment of cancer
|
|
GB201521109D0
(en)
|
2015-11-30 |
2016-01-13 |
Mission Therapeutics Ltd |
Novel compounds
|
|
GB201522267D0
(en)
|
2015-12-17 |
2016-02-03 |
Mission Therapeutics Ltd |
Novel compounds
|
|
GB201522768D0
(en)
|
2015-12-23 |
2016-02-03 |
Mission Therapeutics Ltd |
Novel compounds
|
|
GB201602854D0
(en)
|
2016-02-18 |
2016-04-06 |
Mission Therapeutics Ltd |
Novel compounds
|
|
GB201603779D0
(en)
|
2016-03-04 |
2016-04-20 |
Mission Therapeutics Ltd |
Novel compounds
|
|
GB201604647D0
(en)
|
2016-03-18 |
2016-05-04 |
Mission Therapeutics Ltd |
Novel compounds
|
|
GB201604638D0
(en)
|
2016-03-18 |
2016-05-04 |
Mission Therapeutics Ltd |
Novel compounds
|
|
CN108884068B
(zh)
|
2016-03-24 |
2021-02-26 |
特殊治疗有限公司 |
作为dub抑制剂的1-氰基-吡咯烷衍生物
|
|
US11014912B2
(en)
|
2016-09-27 |
2021-05-25 |
Mission Therapeutics Limited |
Cyanopyrrolidine derivatives with activity as inhibitors of USP30
|
|
GB201616511D0
(en)
|
2016-09-29 |
2016-11-16 |
Mission Therapeutics Limited |
Novel compounds
|
|
GB201616627D0
(en)
|
2016-09-30 |
2016-11-16 |
Mission Therapeutics Limited |
Novel compounds
|
|
TWI771327B
(zh)
|
2016-10-05 |
2022-07-21 |
英商使命醫療公司 |
新穎化合物
|
|
US10968172B2
(en)
|
2017-05-15 |
2021-04-06 |
Mitobridge, Inc. |
USP30 inhibitors
|
|
GB201708652D0
(en)
|
2017-05-31 |
2017-07-12 |
Mission Therapeutics Ltd |
Novel compounds and uses
|
|
GB2563595B
(en)
|
2017-06-19 |
2020-04-15 |
Edwards Ltd |
Twin-shaft pumps
|
|
CN110831936B
(zh)
|
2017-06-20 |
2023-03-28 |
特殊治疗有限公司 |
具有dub抑制剂活性的取代氰基吡咯烷
|
|
AU2018346597B2
(en)
|
2017-10-06 |
2023-07-13 |
Forma Therapeutics, Inc. |
Inhibiting Ubiquitin Specific Peptidase 30
|
|
GB2571731A
(en)
|
2018-03-06 |
2019-09-11 |
Mission Therapeutics Ltd |
Novel compounds and uses
|
|
JP7449242B2
(ja)
|
2018-05-17 |
2024-03-13 |
フォーマ セラピューティクス，インコーポレイテッド |
ユビキチン特異的ペプチダーゼ３０（ｕｓｐ３０）阻害剤として有用な縮合二環化合物
|
|
US11572374B2
(en)
|
2018-08-14 |
2023-02-07 |
Amgen Inc. |
N-cyano-7-azanorbornane derivatives and uses thereof
|
|
JP7530889B2
(ja)
|
2018-10-05 |
2024-08-08 |
フォーマ セラピューティクス，インコーポレイテッド |
ユビキチン特異的プロテアーゼ３０（ｕｓｐ３０）阻害剤として作用する縮合ピロリン
|
|
GB201905371D0
(en)
|
2019-04-16 |
2019-05-29 |
Mission Therapeutics Ltd |
Novel compounds
|
|
GB201905375D0
(en)
|
2019-04-16 |
2019-05-29 |
Mission Therapeutics Ltd |
Novel compounds
|
|
GB201912674D0
(en)
|
2019-09-04 |
2019-10-16 |
Mission Therapeutics Ltd |
Novel compounds
|
|
JP2023520727A
(ja)
|
2020-04-08 |
2023-05-18 |
ミッション セラピューティクス リミティド |
Ｕｓｐ３０阻害剤として活性を有するｎ－シアノピロリジン
|
|
IL298526A
(en)
|
2020-05-28 |
2023-01-01 |
Mission Therapeutics Ltd |
N-(1-cyano-pyrrolidin-3-yl)-5-(3-(trifluoromethyl)phenyl)oxazole-2-carboxamide derivatives and the corresponding oxadiazole derivatives as usp30 inhibitors for the treatment of mitochondrial dysfunction
|
|
US20230303547A1
(en)
|
2020-06-04 |
2023-09-28 |
Mission Therapeutics Limited |
N-cyanopyrrolidines with activity as usp30 inhibitors
|
|
DK4161929T3
(da)
|
2020-06-08 |
2025-08-18 |
Mission Therapeutics Ltd |
1-(5-(2-cyanopyridin-4-yl)oxazol-2-carbonyl)-4-methylhexahydropyrrolo[3,4-b]pyrrol-5(1h)-carbonitril som usp30-hæmmer til anvendelse i behandling af mitokondriedysfunktion, cancer og fibrose
|
|
GB202016800D0
(en)
|
2020-10-22 |
2020-12-09 |
Mission Therapeutics Ltd |
Novel compounds
|